Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNIFF Multi-Device Study 2
NCT04199767Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Generex Oral-lyn in Mild Cognitive Impairment (MCI), sponsored by Wake Forest University Health Sciences. Started Jul 2020; status: completed.
02
Drugs
Generex Oral-lyn
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04199767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04199767.